The second act is where this quarter's money was made

Extension beat invention

Read the latest batch of third-quarter reports and a pattern emerges. The companies with the most convincing quarters were not selling a story about the next asset. They were widening the reach of one already earning money.

BioCryst is the cleanest example. ORLADEYO brought in $174.8 million of its $180.3 million total net revenue. The company then secured FDA approval for 150 mg oral pellets in patients aged 12 and older, launched pellets in pediatric patients, and moved its specialty pharmacy to CareMed. None of that is a new molecule. All of it is work on the franchise, and it supported a non-GAAP operating profit of $86.5 million and lower non-GAAP operating expense guidance of $415 to $425 million.

Keenova follows the same logic. Acthar Gel ($227 million) and XIAFLEX ($164 million) drove $550 million of continuing net sales, and the company raised full-year guidance on higher XIAFLEX growth expectations. Its pipeline is mostly more XIAFLEX: a plantar fibromatosis sBLA expected in the first quarter of 2027 and a hammer toe Phase 3 study that has begun enrolling.

Zymeworks shows the royalty version. First-line gastroesophageal adenocarcinoma approval for Ziihera expanded its royalty opportunity and triggered a $250 million U.S. milestone, which lifted 2026 revenue guidance to $337 million to $351 million from $278 million to $292 million. Innoviva grew U.S. net product sales 45% to $43.3 million and still collected $58.1 million from its royalty portfolio. TransMedics, in a different corner, grew service revenue 60% and has completed enrollment in Part A of its next-generation Organ Care System, so its platform is evolving while the current one scales.

Why this is the smarter bet

The second act carries a different risk profile from the first. The product already has a payer relationship, a prescriber base and a manufacturing process. The incremental question is whether a new label, a new age group or a better dosage form adds revenue, not whether the drug works at all. That is a narrower and more manageable risk, and this season's guidance revisions suggest the market for these assets is rewarding it.

The strongest counter-argument

Extension strategies concentrate exposure, and concentration can punish. Organogenesis reported third-quarter net revenue of $45.5 million against $150.5 million a year earlier. Advanced Wound Care revenue fell 73%, and the company swung to a $29.6 million net loss from $21.6 million of net income. The material does not explain the cause, so we will not guess, but the lesson holds on its own terms: when one segment carries a business, a single move in that segment can erase most of it.

Extension is also not the same as profitability. Keenova posted a $96 million loss from continuing operations in the same quarter that it reported $233 million of adjusted EBITDA. BioCryst held its ORLADEYO guidance at $625 million to $645 million, so the pellet and pharmacy work this quarter broadened the franchise without lifting its outlook. A second act can defend an asset as much as grow it.

Our position

Even so, the evidence favors the second act. The failures this season were about dependence on one revenue source, not about extension itself. Companies that broaden how a proven asset is used, delivered or monetized, while keeping an eye on concentration, are building the more reliable earnings. Executives should stop treating lifecycle work as the unglamorous cousin of discovery. This quarter, it paid the bills.

— The Editor, CompePharma